Last reviewed · How we verify
TMB-001
TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity.
TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity. Used for Onychomycosis (fungal nail infection), Other fungal skin infections.
At a glance
| Generic name | TMB-001 |
|---|---|
| Sponsor | Timber Pharmaceuticals Inc. |
| Drug class | Topical antifungal |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
TMB-001 is being developed by Timber Pharmaceuticals as a novel topical treatment for fungal dermatological conditions. The drug is formulated to penetrate affected skin tissue and target fungal pathogens, with the goal of providing improved efficacy and safety compared to existing topical antifungals.
Approved indications
- Onychomycosis (fungal nail infection)
- Other fungal skin infections
Common side effects
Key clinical trials
- The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis (PHASE3)
- A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMB-001 CI brief — competitive landscape report
- TMB-001 updates RSS · CI watch RSS
- Timber Pharmaceuticals Inc. portfolio CI